Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Clinical-stage biopharmaceutical company targeting cancer resistance.
ORIC Pharmaceuticals has raised $103.0M across 2 funding rounds.
ORIC Pharmaceuticals has raised $103.0M in total across 2 funding rounds.
ORIC Pharmaceuticals has raised $103.0M across 2 funding rounds. Most recently, it raised $50.0M Series C in February 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 21, 2018 | $50M Series C | — | EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Kravis Investment Partners, Memorial Sloan Kettering Cancer Center, NS Investment, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund, Trinitas Capital | Announced |
| Dec 2, 2015 | $53M Series B | — | EcoR1 Capital, Foresite Capital, Kravis Investment Partners, Carl Gordon, Peter Svennilson, LEO Guthart | Announced |
ORIC Pharmaceuticals has raised $103.0M in total across 2 funding rounds.
ORIC Pharmaceuticals's investors include EcoR1 Capital, Fidelity Management & Research Company, Foresite Capital, Kravis Investment Partners, Memorial Sloan Kettering Cancer Center, NS Investment, OrbiMed, Taiho Ventures, The Column Group, Topspin Fund, Trinitas Capital, Carl Gordon.